Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Norihiko Takemoto

Citation

Annals of Oncology (2019) 30 (suppl_5): v756-v759. 10.1093/annonc/mdz267

Authors

N. Takemoto1, J. Miyabe2, T. Fukusumi1, M. Suzuki1, H. Inohara1

Author affiliations

  • 1 Department Of Otorhinolaryngology-head And Neck Surgery, Osaka University Graduate School of Medicine, 565-0871 - Suita/JP
  • 2 Department Of Head And Neck Surgery, Osaka International Cancer Institute, 541-8567 - Osaka/JP
More

Resources

Abstract 2137

Background

The management of papillary thyroid carcinoma (PTC) should be decided by Risk-adapted approach. However, intermediated risk PTC needs to be stratified more precisely. Otherwise, the utility of 18F-FDG PET images in patients with PTC is restrictive. The aim of this study was to investigate the prognostic value of Metabolic Tumor Volume (MTV) measured on 18F-FDG PET images in patients with papillary thyroid carcinoma treated with surgery.

Methods

We retrospectively analyzed 102 patients with PTC who underwent 18F-FDG PET/CT between Feburary 2009 and June 2017 at Osaka University Medical School Hospital for initial staging before surgery. We evaluated the association of MTV of primary tumor (T-MTV) with relapse-free survival (RFS) using Cox regression analysis. Receiver operating characteristic (ROC) curves were used to estimate the optimal cut-off values for T-MTV. We also conducted recursive partitioning analyses to offer a novel risk stratification system.

Results

The 3-year RFS for all patients were 81.2% with median follow-up of 42 months (range 11-111). In Cox model, T-MTV (Hazard Ratio, 1.23; 95% CI, 1.08 to 1.38; P = 0.002) was significantly associated with RFS. ROC analyses showed that the optimal cutoff value of T-MTV was 10.3ml. We classified the patients as having a low, intermediate, or high risk of relapse or death on the basis of T-MTV and lymph node metastasis.

Conclusions

MTV of primary tumor was a significant prognostic factor for RFS in patients with PTC treated with surgery. Incorporation of T-MTV into staging may lead to a better risk stratification.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings